Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: COPD, Emphysema or COPD, Chronic Bronchitis
Interventions: Treatment Then Placebo, Placebo Then Treatment; Procedure
Lead sponsor: Lung Institute; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Seattle, Washington

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Fazisiran Injection, Placebo; Drug · Other
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more

Conditions: Cirrhosis, Liver
Interventions: Ceftriaxone, Normal saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatorenal Syndrome
Interventions: Terlipressin, Placebo; Drug · Other
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 59
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1073, mRNA-1010, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 14
States / cities: Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more

Conditions: Cough
Interventions: Citric Acid; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions: Haloperidol + lorazepam, Loxapine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions: recombinant human CC10 (rhCC10), placebo; Drug
Lead sponsor: Clarassance, Inc.; Industry
Eligibility: 24 Weeks to 29 Weeks
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 4
States / cities: Wilmington, Delaware • Baltimore, Maryland • Mineola, New York

Conditions: Migraine
Interventions: Timolol, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acute Kidney Injury
Interventions: ANG-3777, Placebo; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 18 more

Conditions: COVID-19 (Healthy Volunteers)
Interventions: CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more

Conditions: Healthy
Interventions: IM Saline Placebo (0.25 ml), IM Estradiol valerate (2.5 mg), IM Saline Placebo (0.5 ml), IM Estradiol valerate (5.0 mg), Oral Micronized Progesterone, Oral Placebo, Ghrelin (0.3 ug/kg), Medroxyprogesterone - Acetate; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 80 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimer Disease
Interventions: TB006, Sterile saline (Placebo); Drug · Other
Lead sponsor: TrueBinding, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Long Beach, California

Conditions: COVID-19, Sars-CoV-2 Infection
Interventions: NVX-CoV2705, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 50 Years to 65 Years
Enrollment: 6,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 99
States / cities: Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more

Conditions: Healthy Subjects
Interventions: CDX-0159, Normal saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Acute Kidney Injury
Interventions: THR-184, Placebo; Drug
Lead sponsor: Thrasos Innovation, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 26 more

Conditions: Distributive Shock
Interventions: Angiotensin II, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stable Atherothrombotic Disease
Interventions: CSL112 (reconstituted high density lipoprotein), Placebo; Biological
Lead sponsor: CSL Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Chula Vista, California • Jacksonville, Florida • Miami, Florida + 8 more

Conditions: Pain
Interventions: Lidocaine, Placebo-Saline; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Postoperative Pain
Interventions: Acetaminophen, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Controls
Interventions: Ketamine, Normal saline; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Sacramento, California • New Haven, Connecticut • New York, New York

Conditions: Subarachnoid Hemorrhage, Aneurysmal, Headache
Interventions: Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone, Placebo Pteryogpalatine Fossa Injection; Drug · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Gainesville, Florida • Miami, Florida • Stuart, Florida + 10 more

Conditions: Pleural Effusion
Interventions: LTI-01, Placebo; Drug
Lead sponsor: Rein Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 27 more

Search by objective public record fields.

Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

Prophylactic Antibiotics in Admitted Cirrhotics

Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Esophageal Motility in Reflux Induced Cough

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

Efficacy and Safety of NVX-CoV2705

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

Angiotensin II for Distributive Shock

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

Lidocaine Analgesia For Removal Of Wound Vac Dressings

Intravenous Acetaminophen in Craniotomy

Biomarker Assessment of Glutamatergic Target Engagement

BLOCK-SAH - PPF-Block for Post-SAH Headache

A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions